Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Study to Assess Safety of Concurrent Azeliragon With Craniospinal Irradiation in Patients With Leptomeningeal Metastasis From Solid Tumor Malignancies or High-Grade Gliomas

NCT06724926 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT06724926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06724926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Study to Assess Safety of Concurrent Azeliragon With Craniospinal Irradiation in Patients With Leptomeningeal Metastasis From Solid Tumor Malignancies or High-Grade Gliomas
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 18, 2025
Completion date
January 31, 2031
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma, leptomeningeal metastasis, solid tumor